MX2018002746A - Compuestos de sulfonamida como moduladores de canal de sodio regulado por voltaje. - Google Patents

Compuestos de sulfonamida como moduladores de canal de sodio regulado por voltaje.

Info

Publication number
MX2018002746A
MX2018002746A MX2018002746A MX2018002746A MX2018002746A MX 2018002746 A MX2018002746 A MX 2018002746A MX 2018002746 A MX2018002746 A MX 2018002746A MX 2018002746 A MX2018002746 A MX 2018002746A MX 2018002746 A MX2018002746 A MX 2018002746A
Authority
MX
Mexico
Prior art keywords
voltage
gated sodium
sulfonamide compounds
sodium channel
channel modulators
Prior art date
Application number
MX2018002746A
Other languages
English (en)
Inventor
Ramdas Vidya
Arun Joshi Advait
Kumar Das Amit
Sahebrao Walke Deepak
Maganlal Loriya Rajeshkumar
P Palle Venkata
Hussain Khan Talha
Kumar Kamboj Rajender
Madhukar Kalhapure Vaibhav
Navinchandra Gote Ganesh
Shamlal Datrange Laxmikant
Rangrao Patil Pradeep
Banerjee Moloy
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2018002746A publication Critical patent/MX2018002746A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de sulfonamida de la Formula (I), en donde los sustituyentes son como se describen en la presente, y su uso en una medicina para el tratamiento de enfermedades, trastornos asociados con la inhibición de canales 5 de sodio modulados por voltaje (VGSC), particularmente NaV1.7. Se refiere, además, a los compuestos de este documento y sus sales farmacéuticamente aceptables, sus composiciones farmacéuticas útiles en el tratamiento de enfermedades, trastornos, síndromes y/o condiciones asociadas con la inhibición de canales de sodio regulados por voltaje (VGSC), particularmente NaV1.7. La invención también se 10 refiere al proceso para la preparación de los compuestos de la invención.
MX2018002746A 2015-09-04 2016-09-03 Compuestos de sulfonamida como moduladores de canal de sodio regulado por voltaje. MX2018002746A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3420MU2015 2015-09-04
IN201621011342 2016-03-31
PCT/IB2016/055291 WO2017037682A1 (en) 2015-09-04 2016-09-03 Sulfonamide compounds as voltage-gated sodium channel modulators

Publications (1)

Publication Number Publication Date
MX2018002746A true MX2018002746A (es) 2019-04-25

Family

ID=56990675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002746A MX2018002746A (es) 2015-09-04 2016-09-03 Compuestos de sulfonamida como moduladores de canal de sodio regulado por voltaje.

Country Status (15)

Country Link
US (1) US10239869B2 (es)
EP (1) EP3344621A1 (es)
JP (1) JP2018529668A (es)
KR (1) KR20180049010A (es)
CN (1) CN108349957A (es)
AU (1) AU2016314355A1 (es)
CA (1) CA2996263A1 (es)
EA (1) EA201890616A1 (es)
HK (1) HK1257729A1 (es)
IL (1) IL257703A (es)
MX (1) MX2018002746A (es)
PH (1) PH12018500469A1 (es)
TW (1) TW201722938A (es)
WO (1) WO2017037682A1 (es)
ZA (1) ZA201801501B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018163077A1 (en) 2017-03-08 2018-09-13 Lupin Limited Indanyl compounds as voltage gated sodium channel modulators
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
CN110885328B (zh) * 2018-09-10 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
CA2607670A1 (en) * 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
US8466188B2 (en) 2006-10-12 2013-06-18 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046084A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046049A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
US8124610B2 (en) 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AU2009303468B2 (en) 2008-10-17 2014-08-28 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (en) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Spiro-condensed indole derivatives as sodium channel inhibitors
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010151595A1 (en) 2009-06-26 2010-12-29 Schering Corporation Pyrrolo-benzo-1,4-diazines useful as sodium channel blockers
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2771472A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EP2595989B1 (en) 2010-05-06 2016-07-13 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
US9346798B2 (en) 2012-02-13 2016-05-24 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US9776995B2 (en) * 2013-06-12 2017-10-03 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
EP3126360A1 (en) * 2014-03-29 2017-02-08 Lupin Limited Sulfonamide compounds as voltage gated sodium channel modulators

Also Published As

Publication number Publication date
CN108349957A (zh) 2018-07-31
HK1257729A1 (zh) 2019-10-25
IL257703A (en) 2018-04-30
JP2018529668A (ja) 2018-10-11
AU2016314355A1 (en) 2018-03-15
CA2996263A1 (en) 2017-03-09
EP3344621A1 (en) 2018-07-11
ZA201801501B (en) 2018-12-19
US10239869B2 (en) 2019-03-26
EA201890616A1 (ru) 2018-08-31
WO2017037682A1 (en) 2017-03-09
KR20180049010A (ko) 2018-05-10
PH12018500469A1 (en) 2018-09-10
TW201722938A (zh) 2017-07-01
US20180186777A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
EA032928B1 (ru) Бициклические кетосульфонамидные соединения
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
PH12018500061A1 (en) Oxysterols and methods of use thereof
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
SG10201907291QA (en) Monomethylfumarate prodrug compositions
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
EA201791398A1 (ru) Производные фумагиллола
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.